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Apigenin, a common dietary ﬂavonoid, has been shown to possess anti-tumor properties. However,
the mechanism by which apigenin inhibits cancer cells is not fully understood. Id1 (inhibitor of dif-
ferentiation or DNA binding protein 1) contributes to tumorigenesis by stimulating cell prolifera-
tion, inhibiting cell differentiation and facilitating tumor neoangiogenesis. Elevated Id1 is found
in ovarian cancers and its level correlates with the malignant potential of ovarian tumors. There-
fore, Id1 is a potential target for ovarian cancer treatment. Here, we demonstrate that apigenin
inhibits proliferation and tumorigenesis of human ovarian cancer A2780 cells through Id1. Apigenin
suppressed the expression of Id1 through activating transcription factor 3 (ATF3). Our results may
elucidate a new mechanism underlying the inhibitory effects of apigenin on cancer cells.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction 2. Materials and methodsId (inhibitor of differentiation or DNA binding) proteins belong
to the helix-loop-helix (HLH) family of transcription factors [1]. Id
conventionally alludes to the ability of these proteins to inhibit
DNA binding and differentiation. Id proteins, lacking the basic do-
main for DNA binding, associate with other members of the HLH
family and prevent them from binding DNA or forming active het-
erodimers. There are four members of the Id family, Id1, Id2, Id3,
and Id4. Recent studies suggest that Id proteins may function as
oncogenes [2–4]. Expression of Id proteins has been demonstrated
in a variety of human tumors [2,5–10]. Elevated Id1 expression has
been seen in over 20 types of human cancers including prostate,
breast, cervical, colon, liver, and ovarian cancers [11]. Overexpres-
sion of Id1 promotes cancer cell proliferation and resistance
against apoptosis [12,13]. Id1 has also been suggested to take part
in the malignant progression of human cancers [5,6,14].
Apigenin (40,5,7,-trihydroxyﬂavone) is a common dietary ﬂavo-
noid and is widely distributed in fruits and vegetables [15]. Apige-
nin is used as a healthy food supplement and has been shown to
possess anti-tumor properties [16–19]. However, the mechanisms
that apigenin inhibits cancer cells are not fully understood. In this
manuscript, we have demonstrated that apigenin inhibits human
ovarian cancer A2780 cells through Id1. Our results provide a
new sight into the mechanisms that apigenin inhibits cancer cells.chemical Societies. Published by E
NA binding protein 1; ATF3,2.1. Reagents and cell culture
Apigenin, cycloheximide (CHX), and b-actin antibody were from
Sigma (St. Louis, MO). The antibodies against Id1 and ATF3 (activat-
ing transcription factor 3) were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA). Human ovarian cancer A2780 and
OVCAR3 cells were maintained as described [19]. The A2780 cell
line was established from tumor tissue from an untreated patient.
OVCAR3 cell line was established from the malignant ascites of a
patient with progressive adenocarcinoma of the ovary.
2.2. Reverse-transcriptional PCR (RT-PCR)
Total cellular RNA was prepared and used for cDNA synthesis in a
regular way. The primers used for Id1 are 50-CCTGCCCTGCTGGACGAG-
30 (forward) and 50-ATCTCGCCGTTGAGGGTGC-30 (reverse). The primers
used for ATF3 are 50-GCTAAGCAGTCGTGGTATGGG-30 (forward) and
50-TCCTGGAGTTGAGGCAAAGAT-30 (reverse). The primers used for
GAPDH are 50-CCACCCATGGCAAATTC CATGGCA-30 (forward) and
50-TCTAGACGGCAGGTCAGGTCCACC-30 (reverse).
2.3. Plasmids
cDNA of Id1 were cloned into HindIII and Xho I sites of pcDNATM
3.1/myc-His A vector. The primers used for cloning Id1 are: 50-AAA
AAAGCTTCCACCATGAAAGTC-30 (forward) and 50-AAAACTCGAGT-
CAGCGACACAAG-30 (reverse). For constructing ATF3, a 546 bp oflsevier B.V. All rights reserved.
2000 Z.-d. Li et al. / FEBS Letters 583 (2009) 1999–2003ATF3 cDNA was subcloned into HindIII and BamHI sites of pcDNA
3.1. The primers for cloning ATF3 are: 50-AAAAAGCTTCCACCATGAT
GCTTCAACACCCA-30 (forward) and 50-AAAGGATCCTTAGCTCTGCA
ATGTTCCT-30 (reverse).
2.4. siRNA
The sequence of Id1 siRNA is 50-AACGGCTGTTACTCACGCCTC-30
(si-Id1) and that of control siRNA is 50-ACTACCGTTGTTATAGGTGT-30.
The sequence of Id1 siRNA was submitted for BLAST search to
ensure that only Id1 was targeted. pSilencer 2.0-U6 vector from
Ambion (Austin, TX) was used to construct the siRNAs. For knock-
ing down ATF3, two ATF3 siRNA oligoes (siATF3-1 and siATF3-2)
and control siRNA oligo were purchased from Gene Pharma
(Shanghai, China). The sequences of these oligoes are:
siATF3-1: CCUCUUUAUCCAACAGAUATT
siATF3-2: GGUUGUGCUUUCUAGCAAATT
Control: UUCUCCGAACGUGUCACGUTT
2.5. Transient transfection
The cells at 60–70% conﬂuence were transfected with plasmids
or siRNA oligoes using Lipofectamine and Plus reagents from Invit-
rogen as per the manufacture’s instruction.
2.6. The orthotopic mouse ovarian cancer model
This experiment was performed as described previously [20]. In
brief, 4-week-old female nude mice (Balb/c) were injected with0
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Fig. 1. Apigenin inhibits proliferation of ovarian cancer cells. (A) A2780 and OVCAR3 cells
added and cells were treated for 24 and 48 h, respectively. Cell proliferation was determ
Cells treated with solvent alone were used as control. (B) Apigenin arrests A2780 cells a
described previously [44]. Brieﬂy, A2780 cells were seeded onto six-well plates and incub
The cells were trypsinized, ﬁxed with ice-cold ethanol (70%), stained with propidium iod
cells. Orthotopic mice ovarian tumor implantation and treatment of mice with apigenin w
were randomly selected for immunoblotting analysis.A2780 cells subcutaneously at the rear ﬂanks. Tumors were al-
lowed to develop until they reach 15–20 mm3 in size. These mice
were sacriﬁced and 3-mm3 pieces of the tumor were excised for
orthotopic implantation. Additional 4-week-old female nude mice
were anesthetized with nembutal. A right lateral incision was
made and part of the right ovary was well exposed. One tissue
block was implanted on the ovarian capsule. After transplantation,
the skin was closed and the mice were divided randomly into two
groups (each group containing 11 mice). In 2 days, apigenin (5 mg/
kg body weight) was administered, IP, once a day. The apigenin
dose was chosen according to previous work [21]. Primary tumors
were allowed to develop for 30 days. The primary tumor size was
measured using digital vernier caliper. Tumor volumes were calcu-
lated using the equation: volume = (p  a  b2)/6, where, a is the
longer dimension and b is the shorter dimension [22,23].
2.7. Statistics analysis
The data represent mean ± S.D. from three independent experi-
ments except where indicated. Statistical analysis was performed
by Student’s t test at a signiﬁcance level of P < 0.05.
3. Results
3.1. Apigenin inhibits proliferation and tumor growth of ovarian
cancer A2780 cells
The effects of apigenin on proliferation of ovarian cancer cells
were determined. As shown in Fig. 1, apigenin inhibited prolifera-ID1
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were seeded in a six-well plate and incubated overnight. The next day, apigenin was
ined by counting the cell numbers by using haemocytometer under a microscope.
t G2/M stage and induces apoptosis of the cells. Flow cytometry was performed as
ated overnight. The next day, apigenin was added and the cells were treated for 24 h.
ide, and subjected to FACS analysis. (C) Apigenin inhibited tumor growth of A2780
as as described in Methods. Four primary tumors from vehicle and apigenin groups
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manner. We next determined the effects of apigenin on A2780 cells
by means of Flow cytometry. Apigenin treatment induced cell cycle
arrest of A2780 cells at G2/M stage (Fig. 1B), eliciting an anti-pro-
liferative effect of apigenin via blocking the cell cycle. This is con-
sistent with previous reports that apigenin arrests cells at G2/M
phase [17,18,24]. Apigenin at 20 lM did not induce apoptosis of
the cells. However, at higher concentration (40 lM), apigenin
treatment caused apoptosis of the cells (Fig. 1B).
Finally, we determined the effects of apigenin on tumor growth
of A2780 cells in nude mice. The in vivo animal experiment indi-
cates that administration of mice with apigenin repressed the
growth of A2780 xenografts (Fig. 1C). Immunoblotting analysis of
the primary tumor extracts showed that apigenin treatment atten-
uated expression of ID1 (Fig. 1C).
3.2. Apigenin inhibits expression of Id1 at a transcriptional level
Apigenin inhibited expression of Id1 at a dose- and time-depen-
dent manner (Fig. 2A and B). Treatment of A2780 cells with CHX,Id1
β-actin
Api (µM)        0      10      20     40 Time (h)      0       4         8     12
Id1  
β-actin
Id1
GAPDH
Id1
GAPDH
Fig. 2. Apigenin inhibits Id1 expression. (A) Apigenin inhibited expression of Id1 at
a dose-dependent manner. A2780 cells were treated with different concentrations
of apigenin for 8 h. Immunoblotting and RT-PCR were performed as described under
Methods. (B) Apigenin inhibited expression of Id1 at a time-dependent manner.
A2780 cells were treated with apigenin (40 lM) for different hours as indicated.
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Fig. 3. Apigenin inhibits Id1 expression through ATF3. (A) Apigenin induced expression o
cellular proteins and total RNA were prepared. Immunoblotting and RT-PCR were perf
apigenin (40 lM) for different hours. The cells were harvested and cellular proteins
suppressed expression of Id1. A2780 cells were transfected with ATF3 or control vect
determined. (D) Knockdown of ATF3 restored Id1 expression inhibited by apigenin. A
transfection, the cells were treated with 40 lM of apigenin for 12 h. The cells were then h
antibodies. Api, apigenin.an inhibitor of protein synthesis, led to a decrease of Id1 protein
to the same extent as treatment with CHX plus apigenin did (data
not shown). The data suggest that apigenin does not inﬂuence sta-
bility of Id1 protein. We found that apigenin treatment decreased
mRNA levels of Id1 (Fig. 2), suggesting that apigenin regulates
Id1 expression at mRNA level. It has been reported that ATF3 reg-
ulates expression of Id1 transcriptionally [25]. Therefore, we next
determined whether ATF3 was involved in Id1 regulation by apige-
nin. Treatment of A2780 cells with apigenin induced expression of
ATF3 and inhibited that of Id1 (Fig. 3A and B). We found that over-
expression of ATF3 suppressed expression of Id1 (Fig. 3C). These
data suggest that apigenin may inhibit Id1 through ATF3. To con-
ﬁrm this, we determined whether knockdown of ATF3 could re-
store Id1 expression after apigenin treatment. We found that
knockdown of ATF3 indeed rescued expression of Id1 (Fig. 3D).
Altogether, these results suggest that apigenin inhibits Id1 expres-
sion through ATF3.
3.3. Apigenin inhibits A2780 cell proliferation through Id1
Knockdown of Id1 inhibited proliferation of A2780 cells
(Fig. 4A), indicating that Id1 plays a role on A2780 cells prolifera-
tion. To know whether apigenin inhibited proliferation of A2780
cells via Id1, A2780 cells were transfected with Id1 and then trea-
ted with apigenin. Overexpression of Id1 partially restored prolif-
eration of A2780 cells inhibited by apigenin (Fig. 4B). We next
determined whether the ATF3 knockdown could restore prolifera-
tive capacity of A2780 cells in the presence of apigenin. As shown
in Fig. 4C, knockdown of ATF3 partially restored proliferation of
A2780 cells as well.
4. Discussion
Apigenin has been shown to be capable of inhibiting growth of a
few types of human cancer cells including leukemia and carcino-
mas of breast, colon, lungs, skin, thyroid, and prostate. A number
of molecular mechanisms for anti-carcinogenic activity of apigeninHour         0       2       4      8      12
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Fig. 4. Apigenin inhibits A2780 proliferation through Id1. (A) Knockdown of Id1
inhibited proliferation of A2780 cells. A2780 cells were transfected with si-Id1 or
control siRNA and split to a 24-well plate. In 24 h post-transfection, cell prolifer-
ation was determined by cell counting as described in Fig. 1A. (B) Overexpression of
Id1 restored proliferation of A2780 cells inhibited by apigenin. A2780 cells were
transfected with Id1 or control vector and split to six-well plates. In 24 h post-
transfection, apigenin (20 lM) was added and incubation continued for another
24 h. Cell proliferation was determined as described above. (C) Knockdown of ATF3
restored cell proliferation by apigenin. A2780 cells were transfected with siATF3 or
control siRNA oligoes and split to six-well plates. In 24 h post-transfection, the cells
were incubated with apigenin (20 lM) for another 24 h. Cell proliferation was
determined as described. **P < 0.01; *P < 0.05.
2002 Z.-d. Li et al. / FEBS Letters 583 (2009) 1999–2003have been proposed [26]. For example, apigenin has been shown to
modulate the PI3K/AKT signaling [19,27], the insulin-like growth
factor growth axis [28], and beta-catenin signaling [29]. Although
several pathways have been proposed, the mechanisms that apige-
nin inhibits cancer cells are not fully understood. Here, we have
demonstrated that apigenin inhibits proliferation of ovarian cancer
cells through Id1.
The level of Id1 expression correlates with the malignant poten-
tial of ovarian tumors [30]. In cancer samples, high Id1 expression
is associated with poor differentiation and more aggressive behav-
ior of tumor cells. It was found in vitro that expression of Id1 pro-
mote proliferation of ovarian cancer cells [31]. These results
suggest that Id1 is a potential target for the development of novel
strategies in the treatment of ovarian cancer.
Knockdown of Id1 inhibits proliferation of A2780 cells (Fig. 4A),
and overexpression of Id1 partly restores cell proliferation inhib-
ited by apigenin (Fig. 4B). Moreover, knockdown of ATF3, which re-
stores expression of Id1 in apigenin-treated cells (Fig. 3D), also
partially restores proliferative capacity of A2780 cells (Fig. 4C).
These results suggest that apigenin inhibits proliferation of ovarian
cancer cells, at least partially, through Id1. In addition to Id1, api-
genin may have other targets. So, we cannot exclude the possibility
that apigenin inhibits proliferation of A2780 cells through other
pathways. We found that apigenin decreased mRNA levels of Id1
(Fig. 2) but had little effects on its protein stability (data not
shown), suggesting that apigenin inhibits Id1 expression at a tran-
scriptional level. Our results are consistent with the recent report
that expression of Id1 was regulated at a transcriptional level
[32]. ATF3 is a member of the ATF/CREB family of transcription fac-
tors. ATF3 is expressed at low levels in normal and quiescent cells,
but can be rapidly induced in response to diverse stress signals
[33–36]. In most cases ATF3 was found to repress transcriptionof target genes [37,38]. We found that apigenin induced ATF3
(Fig. 3A) and overexpression of ATF3 suppressed expression of
Id1 (Fig. 3C). Moreover, knockdown of ATF3 could restore Id1
expression inhibited by apigenin (Fig. 3D). Taken together, these
results suggest that apigenin inhibits expression of Id1 via ATF3.
Apigenin inhibited proliferation of many types of cancer cells
and a number of molecular mechanisms have been proposed
[26]. For example, apigenin can inhibit growth of breast cancer
cells as both an antiestrogen and a protein kinase inhibitor [39].
A recent study indicates that apigenin inhibited proliferation of
prostate cancer cells via IGF-1/IGF-1R axis [40]. These results sug-
gest that apigenin may have multiple targets. We have demon-
strated herein that apigenin inhibits proliferation of ovarian
cancer cells through, at least partially, ATF3/Id1 pathway. There
is growing evidences that higher intake of plant ﬂavonoids reduces
the risk of certain chronic diseases including cancer [41–43]. Our
results provide more evidence that the dietary ﬂavonoid apigenin
might be a potential agent for chemoprevention and/or treatment
of cancers such as ovarian cancer.
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